Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Ranolazine for enhancing insulin secretion

A technology of insulin secretion and ranolazine, applied to endocrine system diseases, medical preparations containing active ingredients, organic active ingredients, etc., can solve the problems of decreased number of insulin receptors, dysfunction of signaling pathways, etc.

Inactive Publication Date: 2010-02-24
GILEAD PALO ALTO
View PDF21 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This failure to respond may be due to a reduced number of insulin receptors on the cell, or dysfunctional intracellular signaling pathways, or both

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ranolazine for enhancing insulin secretion
  • Ranolazine for enhancing insulin secretion
  • Ranolazine for enhancing insulin secretion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0242] Effects of ranolazine or ranolazine R- or S-enantiomer on GSIS in isolated rat islets

[0243] figure 1 The effect of ranolazine on GSIS in rat isolated islets is shown. Rat islets were isolated from male Sprague-Dawley (SD) rats (8-12 weeks old, n=6) and maintained overnight at full RPMI 1640 as described by YangZ.et al.Transplantation 2004, 77, 55-60 . Insulin secretion analysis was performed essentially as previously described by Liu D. et al. Steroids 2006, 71, 691-699. Briefly, before experiments, islets were incubated in Krebs-Ringer bicarbonate buffer (KRB; 129 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO 4 , 1.2mM KH 2 PO 4 , 2.5mM CaCl 2 , 5mM NaHCO 3 , 0.1% BSA, 10mM HEPES, pH 7.4) pre-incubated for 30min, then washed the islets and incubated in 24-well plates in triplicate (50 islets / well), at 37°C in oxidized KRB buffer containing 3mM glucose or Incubate in 20 mM glucose for 60 min in the presence of various concentrations of ranolazine or vehicle. Insulin sec...

Embodiment 2

[0247] Effect of Ranolazine on Insulin Level in Rats

[0248] figure 2 Plasma insulin levels during an intravenous glucose tolerance test (IVGTT) performed in normal SD mice are shown. Each rat underwent IVGTT according to the method of Hendrick et al, Metabolism 42, (1): 1-6, 1993 . Rats were fasted overnight prior to test administration. One group of 11 mice was given saline only before the glucose load, while a second group of 7 mice was given ranolazine before the glucose load. Glucose was given at time 0, and ranolazine was given 30 min before glucose at a dose of 15 mg / kg body weight. Then blood insulin concentration was measured at -30, 0, 2, 4, 7, 15 and 30 min. As seen by plotting time versus baseline insulin levels, insulin levels were higher in ranolazine-treated rats compared to vehicle-treated rats.

Embodiment 3

[0250] Effects of Enantiomers of Ranolazine on Insulin Levels in Rats

[0251] image 3 Insulin levels during an intravenous glucose tolerance test (IVGTT) performed in normal SD rats are shown. The method used was as described in Example 2 above. As seen by plotting time versus baseline insulin levels, insulin levels were higher in rats treated with 15 mg / kg ranolazine R-enantiomer compared to vehicle treated rats. The insulin response to the S-enantiomer was different from vehicle-treated rats.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent.

Description

[0001] This application claims U.S. Provisional Patent Application Serial No. 60 / 911,457 filed April 12, 2007, U.S. Provisional Patent Application Serial No. 60 / 977,009 filed October 2, 2007, and February 5, 2008 Priority to U.S. Provisional Patent Application Serial No. 61 / 026,223, the entire contents of which are hereby incorporated by reference. technical field [0002] The present invention relates to a method for enhancing endogenous insulin levels in a patient in need thereof, the method comprising administering to the patient ranolazine (racemate or (±)) or R- or S of ranolazine to enhance insulin secretion. -Enantiomer. The present invention also relates to therapeutic methods and compositions comprising ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. Background technique [0003] U.S. Patent No. 4,567,264 discloses ranolazine, (±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/495A61K45/06A61P9/00A61P3/10A61P5/50
Inventor 阿尔温德·达尔拉路易斯·贝拉尔迪内利约翰·施赖奥克梁钧衡曾德婉
Owner GILEAD PALO ALTO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com